SynthesisFrontiers in oncology2025
Cuproptosis as a therapeutic target in cancer: a Systematic Review and bibliometric analysis of the research landscape.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Ubiquitin-specific protease 11 suppresses cuproptosis in colorectal cancer by regulating the ubiquitination and stability of ISCU.Oncogenesis · 2026Article
- Therapeutic horizons of cuproptosis: bibliometric mapping of copper-dependent cell death research and its pharmacological implications.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Advancing prussian blue nanoparticle-mediated photothermal therapy through machine learning and multiomics integration.Nanomedicine (London, England) · 2026Review
- TheJournal of gastrointestinal oncology · 2026Article
- Development and Validation of a Cuproptosis-Based Risk Score Model for Predicting Neoadjuvant Chemotherapy Response in Breast Cancer: A Transcriptomic Analysis.The breast journal · 2026Article
- Review
- Non-apoptotic regulated cell death based prognostic risk model for colorectal cancer using machine learning guided two-step framework.Briefings in bioinformatics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cuproptosis is a new form of cell death induced by intracellular copper overload. With the deepening of research, the research of cuproptosis in the field of cancer has become a hot topic. The bibliometric analysis of cuproptosis research can provide valuable insights into the development of this field. Method: In this study, the Web of Science Core Collection database was used to obtain literature, and the screened data were imported into CiteSpace software for analysis. We use this data for visualization analysis and made knowledge maps including authors, countries, institutions, journals, and keywords. Results: 1140 literature was obtained from Web of Science from 2001 to 2024. The results indicate a consistent upward trend in the number of publications in this field. Moreover, a particularly significant surge in the frequency of citations has been observed since 2022. Through a systematic analysis, we found that in the current field of cancer research on cuproptosis, breast cancer, lung cancer, hepatocellular carcinoma and colorectal cancer have more research results. Conclusion: This article describes how copper ions regulate cell death, particularly in cancer therapy, and requires an in-depth understanding of the complexity of copper metabolism and its specific mechanisms of action in cell death. The work provides a panoramic view of the research landscape on cuproptosis in cancer, highlighting its potential as a therapeutic target and the need for further exploration into its mechanisms and clinical applications. With the depth of research, it is expected that cuproptosis will continue to be a hotspot in cancer treatment research. In addition, it provides a solid theoretical foundation and experimental basis for the development of new anti-tumor therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.